Journal of Clinical Oncology
Articles in this Issue
Assessing global trends of cervical cancer: 1990-2021.
e17510 Background: Cervical cancer (CC) ranks as the fourth most common malignancy and the fourth leading cause of cancer-related deaths globally, with mo...
Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).
5093 Background: ENZAMET showed that enzalutamide (ENZ) significantly improves overall survival (OS) of metastatic hormone-sensitive prostate cancer (mHSP...
Analysis of factors affecting aesthetic outcomes and safety in breast-conserving surgery: A multicentre prospective cohort study.
e12569 Background: Breast conservation surgery (BCS) has gradually become the mainstream surgical approach for breast canc...
Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: A randomized controlled trial.
12020 Background: Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. Th...
Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in the GEICAM/2013-02 PEARL trial.
1066 Background: TKa is a proliferation biomarker measurable in blood via the DiviTumâ„¢ TKa assay. Levels of TKa before and during treatment can provide pr...
Epidemiology and outcomes of disseminated intravascular coagulation in pancreatic cancer patients admitted with sepsis: Insights from a national database.
e16376 Background: Disseminated intravascular coagulation (DIC) is a coagulopathy involving systemic thrombosis and increased bleeding risk due to consump...
Pulmonary embolism in cancer patients: Clinical insights and outcomes from a community hospital.
e23084 Background: Pulmonary embolism (PE) is a leading cause of death in cancer patients, driven by hypercoagulability, immobility, and cancer therapies....
Real-world treatment outcomes and clinicopathologic determinants of response for patients with advanced thyroid cancer treated with first-line lenvatinib.
e18132 Background: Lenvatinib, a multi-targeted tyrosine kinase inhibitor, is approved for the treatment of locally recurrent or metastatic, progressive r...
Patient-reported health experiences among US immigrant patients with cancer.
11072 Background: Patients often experience complex, multifaceted challenges while navigating cancer care, including many interactions with the health sys...
Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
TPS3173 Background: Mutations in exon 20 of the EGFR gene account for approximately 4% to 10% of all EGFR mutations in Non-Small C...
Epidemiology of breast cancer and problems of screening.
e13897 Background: Breast cancer is the leading cancer pathology among the female population in terms of incidence and mortality in Uzbekistan. Breast can...
A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).
4596 Background: Radical cystectomy (RC)is the standard treatment forBCG unresponsive high-risk (HR) NMIBC patients (pts). Pembrolizumab (Pem) was approve...
Exploring the cytotoxic effects of bioactive compounds from <i>Alcea rosea</i> against stem cell-driven colon carcinogenesis.
e15538 Background: Seven compounds were isolated from ethyl acetate extract of Alcea rosea and were examined for their cytotoxicit...
Exploring skin toxicity as a predictor of response in urothelial carcinoma patients treated with enfortumab vedotin: A meta-analysis of Kaplan-Meier reconstructed individual patient data.
e16555 Background: Skin toxicity (ST) emerged as an on-target toxicity related to enfortumab vedotin (EV), mainly occurring in the first treatment cycle....
MSLN and CLDN18.2 dual-target CAR-T therapy: Enhancing cancer treatment with improved efficacy and safety.
e16381 Background: While CAR-T cell therapy has been highly successful in treating hematologic malignancies, its application to solid tumors remains chall...
Effect of low-dose rapamycin on the therapeutic response to radio-immunotherapy in hepatocellular carcinoma.
e14611 Background: Numerous clinical trials have demonstrated the efficacy of combined radiotherapy and PD-1 antibody treatment in hepatocellular carcinom...
Evaluating the safety and efficacy of CRISPR/AaCas12b <sup>Max</sup> -modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors.
5613 Background: Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TILs) has shown promising results in melanoma patients. However, i...
Evaluating the comparative effectiveness of clinical trial participation on hospital outcomes among cancer patients: A trend analysis.
e23178 Background: Research, therapy, strategy, and technological progress depend on participation in trials. Numerous randomized controlled trials encoun...
Colorectal cancer in young adults: What social behavior factors may be responsible?
e15706 Background: The incidence of colorectal cancer (CR) is rising amongst younger individuals in the United States. We proposed to evaluate the trends...
Effect of a letter of condolence proposing a post-mortem consultation to the relatives of cancer patients on anxiety, depression and grief: Results of a multicenter randomized study.
12028 Background: The relativesof cancer patients are at risk for developing emotional distress following the death of their loved one. The aim of this st...
GABRP as a biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer (WJOG10417GTR study).
4035 Background: GABRP, Gamma-aminobutyric acid type A receptor subunit π, is a key molecule that influences tumor properties and patient prognosis in var...
A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States.
3581 Background: GCC19CART, the first clinical candidate of the CoupledCAR solid tumor platform, pairs a solid tumor chimeric antigen receptor (CAR) T-cel...
Intravenous vitamin C as an adjunct to standard therapy in pancreatic ductal adenocarcinoma: A systematic review of clinical trials.
e16396 Background: Pancreatic ductal adenocarcinoma (PDAC) is the 3rd leading cause of cancer death, with a 5-year survival rate of just 13%. Vitamin C sh...
Influence of unruptured abdominal aortic aneurysm (AAA) diagnosis on risk of malignant neoplasms in patients with obesity and ischemic heart disease.
e23344 Background: Obesity is associated with risk factors for abdominal aortic aneurysm (AAA), which is associated with cigarette smoking that predispose...
Prevalence of dosage modifications and impact on response milestone among patients with CML treated with imatinib using RWD.
e23335 Background: Continuous treatment with BCR-ABL1 TKIs are the cornerstone of chronic myeloid leukemia (CML) treatment. This study aims to assess the...